keyword
MENU ▼
Read by QxMD icon Read
search

Boehringer Ingelheim

keyword
https://www.readbyqxmd.com/read/29777519/combination-glucose-lowering-therapy-plans-in-t2dm-case-based-considerations
#1
REVIEW
Lawrence Blonde, Susana Dipp, Daniel Cadena
Type 2 diabetes mellitus (T2DM) is a complex disease, and while lifestyle interventions remain the cornerstone of therapy, most patients will also require pharmacotherapy. Current diabetes treatment guidelines and algorithms recommend an individualized approach to setting glycemic goals and selecting treatment. Although a single antihyperglycemic agent may be appropriate as the initial T2DM pharmacotherapy, the progressive nature of the disease due to declining pancreatic β-cell function will result in the vast majority of T2DM patients eventually requiring two or more antihyperglycemic agents...
May 18, 2018: Advances in Therapy
https://www.readbyqxmd.com/read/29744822/study-protocol-for-the-initial-choice-of-dpp-4-inhibitor-in-japanese-patients-with-type-2-diabetes-mellitus-effect-of-linagliptin-on-qol-intel-qol-trial
#2
Tomoya Mita, Toru Hiyoshi, Hidenori Yoshii, Hiroko Chimori, Kazuo Ikeda, Junko Sato, Hirotaka Watada
INTRODUCTION: Consideration of treatment-related quality of life (QOL) is important in diabetes management. However, no studies have compared the influence of dipeptidyl peptidase-4 inhibitors versus metformin on treatment-related QOL when used as first-line therapy in patients with type 2 diabetes mellitus. METHODS: This study is a prospective, randomized, open-label, multicenter, parallel-group, comparative study. Between June 2016 and December 2017, 44 participants who failed to achieve glycemic control despite diet and exercise therapy were recruited at 14 clinics and randomly allocated to linagliptin or metformin therapy...
May 9, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29722630/an-industry-update-the-latest-developments-in-therapeutic-delivery
#3
Oliver C Steinbach
The present industry update covers the period of 1 January-31 January 2018, with information sourced from company press releases, regulatory and patent agencies as well as scientific literature. Several public offerings (Gecko, Insmed), licensing (Foresee) and commercialization agreements (Alnylam, Collegium Pharmaceutical) as well as patent filings (Elute) continue to prove the sustained investments in the drug delivery market. In increasing numbers, more effective ways to deliver the active ingredient to the right location and the right dose through devices (Boehringer Ingelheim's Respimat, Medtronics' SynchroMedII) or improved compound properties through formulation (Aquestive Therapeutics' PharmFilm, Noven Pharmaceuticals' transdermal patch) are reaching the market...
May 1, 2018: Therapeutic Delivery
https://www.readbyqxmd.com/read/29694286/primary-nonadherence-to-oral-anticoagulants-in-patients-with-atrial-fibrillation-real-world-data-from-a-population-based-cohort
#4
Clara L Rodriguez-Bernal, Salvador Peiró, Isabel Hurtado, Aníbal García-Sempere, Gabriel Sanfélix-Gimeno
BACKGROUND: Primary nonadherence (not filling a first prescription) is an important yet unstudied aspect of adherence to oral anticoagulant (OAC) therapy. OBJECTIVE: To estimate the rates of primary nonadherence to OACs and determine associated factors in real-world practice. METHODS: This population-based retrospective cohort study set in the Valencia region of Spain (about 5 million inhabitants) included all patients with atrial fibrillation who were newly prescribed OACs during 2011-2014 (N = 18,715)...
May 2018: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29694284/publicly-funded-oral-chronic-hepatitis-b-treatment-patterns-in-ontario-over-16-years-an-ecologic-study
#5
Mina Tadrous, Mayur Brahmania, Diana Martins, Sandra Knowles, Harry L A Janssen, Muhammad M Mamdani, David N Juurlink, Tara Gomes
BACKGROUND: Reimbursement for the use of hepatitis B virus (HBV) treatments has not been previously reported for public payers. OBJECTIVE: To describe the number of users and total cost of HBV treatments over the last 16 years among residents of Ontario, Canada, who were covered by the public drug program. METHODS: We conducted a repeated cross-sectional study for HBV treatments reimbursed by the public drug program in Ontario from January 1, 2000, to December 31, 2015...
May 2018: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29688615/comparative-pharmacokinetics-and-pharmacodynamics-of-bococizumab-following-a-single-subcutaneous-injection-using-drug-substance-manufactured-at-two-sites-or-administration-via-two-different-devices
#6
Ellen Q Wang, Anna Plotka, Joanne Salageanu, Daniel Baltrukonis, Khurshid Mridha, Robert Frederich, Beth E Sullivan
The pharmacokinetics (PK) and pharmacodynamics (PD) of bococizumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, were compared following a single 150-mg subcutaneous dose administered to healthy subjects (n = 156-158/arm) via: (1) a prefilled syringe (PFS) using drug substance (DS) manufactured by Pfizer, (2) a PFS using DS manufactured by Boehringer Ingelheim Pharma, (3) a prefilled pen using DS manufactured by Pfizer (NCT02458209). Blood samples were collected for 12 weeks postdose...
April 24, 2018: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/29676732/donated-chemical-probes-for-open-science
#7
Susanne Müller, Suzanne Ackloo, Cheryl H Arrowsmith, Marcus Bauser, Jeremy L Baryza, Julian Blagg, Jark Böttcher, Chas Bountra, Peter J Brown, Mark E Bunnage, Adrian J Carter, David Damerell, Volker Dötsch, David H Drewry, Aled M Edwards, James Edwards, Jon M Elkins, Christian Fischer, Stephen V Frye, Andreas Gollner, Charles E Grimshaw, Adriaan IJzerman, Thomas Hanke, Ingo V Hartung, Steve Hitchcock, Trevor Howe, Terry V Hughes, Stefan Laufer, Volkhart Mj Li, Spiros Liras, Brian D Marsden, Hisanori Matsui, John Mathias, Ronan C O'Hagan, Dafydd R Owen, Vineet Pande, Daniel Rauh, Saul H Rosenberg, Bryan L Roth, Natalie S Schneider, Cora Scholten, Kumar Singh Saikatendu, Anton Simeonov, Masayuki Takizawa, Chris Tse, Paul R Thompson, Daniel K Treiber, Amélia Yi Viana, Carrow I Wells, Timothy M Willson, William J Zuercher, Stefan Knapp, Anke Mueller-Fahrnow
Potent, selective and broadly characterized small molecule modulators of protein function (chemical probes) are powerful research reagents. The pharmaceutical industry has generated many high-quality chemical probes and several of these have been made available to academia. However, probe-associated data and control compounds, such as inactive structurally related molecules and their associated data, are generally not accessible. The lack of data and guidance makes it difficult for researchers to decide which chemical tools to choose...
April 20, 2018: ELife
https://www.readbyqxmd.com/read/29661207/repellent-efficacy-of-a-new-combination-of-fipronil-and-permethrin-against-lutzomyia-longipalpis
#8
André Antonio Cutolo, Fredy Galvis-Ovallos, Elisangela de Souza Neves, Fabiano O Silva, S Theodore Chester, Becky Fankhauser
BACKGROUND: Lutzomyia longipalpis is the main vector of Leishmania infantum, the agent of canine and human visceral leishmaniosis in the Americas. Considering that the dog is the main domestic host of the parasite, repellent treatment is a measure that might contribute to the prevention of canine visceral leishmaniosis. The repellent efficacy of a single treatment of a new spot-on topical combination of fipronil and permethrin (Frontline Tri-Act®, Merial, now part of Boehringer-Ingelheim) to repel Lu...
April 16, 2018: Parasites & Vectors
https://www.readbyqxmd.com/read/29607392/colon-cleansing-protocol-in-children-research-conditions-vs-clinical-practice
#9
Yoram Elitsur, Yaslam Balfaqih, Deborah Preston
Background and study aims:  Colon preparation rates are the limiting factor for a successful diagnostic colonoscopy in children. Different colon cleansing protocols have been published for use in children. Unfortunately, the applicability of those published research protocols has not been formally evaluated in routine clinical practice. We investigated the success rate of our previously published colon cleansing protocol as utilized in our clinical practice. Patients and methods:  This was a retrospective study...
April 2018: Endoscopy International Open
https://www.readbyqxmd.com/read/29605624/tiotropium-and-olodaterol-in-the-prevention-of-chronic-obstructive-pulmonary-disease-exacerbations-dynagito-a-double-blind-randomised-parallel-group-active-controlled-trial
#10
Peter M A Calverley, Antonio R Anzueto, Kerstine Carter, Lars Grönke, Christoph Hallmann, Christine Jenkins, Jadwiga Wedzicha, Klaus F Rabe
BACKGROUND: Combinations of long-acting bronchodilators are recommended to reduce the rate of chronic obstructive pulmonary disease (COPD) exacerbations. It is unclear whether combining olodaterol, a long-acting beta-agonist, with tiotropium, a long-acting anti-muscarinic, reduces the rate of exacerbations compared with tiotropium alone. METHODS: This 52-week, double-blind, randomised, parallel-group, active-controlled trial randomly assigned (1:1) patients with COPD with a history of exacerbations using a randomised block design to receive tiotropium-olodaterol 5 μg-5 μg or tiotropium 5 μg once daily...
March 28, 2018: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/29578852/economic-burden-of-patients-with-inadequate-response-to-targeted-immunomodulators-for-rheumatoid-arthritis
#11
Vibeke Strand, Namita Tundia, Yan Song, Dendy Macaulay, Mahesh Fuldeore
BACKGROUND: Targeted immunomodulators (TIMs), including biologic disease-modifying antirheumatic drugs (DMARDs) and JAK/STAT inhibitors, are effective therapies for rheumatoid arthritis (RA), but some patients fail to respond or lose response over time. This study estimated the real-world prevalence of RA patients with inadequate responses to an initial TIM (nonresponders) in the United States and assessed their direct and indirect economic burden compared with treatment responders. METHODS: Administrative claims data (January 1999-March 2014) from a large private-insurer database were used, which included work-loss data from a subset of reporting companies...
April 2018: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29578847/development-of-quality-indicators-to-assess-oral-anticoagulant-management-in-community-pharmacies-for-patients-with-atrial-fibrillation
#12
Mylène Chartrand, Line Guénette, Denis Brouillette, Stéphane Côté, Roger Huot, Jérôme Landry, Josée Martineau, Sylvie Perreault, Brian White-Guay, David Williamson, Élisabeth Martin, Marie-Mireille Gagnon, Lyne Lalonde
BACKGROUND: Few studies have evaluated the quality of oral anticoagulant management by community pharmacists. There is no complete set of quality indicators available for this purpose. OBJECTIVE: To develop a set of specific quality indicators to assess oral anticoagulant management by community pharmacists for patients with atrial fibrillation (AF). METHODS: Quality indicators were developed in 3 phases. In phase 1, potential quality indicators were generated based on clinical guidelines and a literature review...
April 2018: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29571209/boehringer-ingelheim-vr-video-zeigt-zerst%C3%A3-rungskraft-des-prrs-virus-in-der-schweinelunge
#13
(no author information available yet)
No abstract text is available yet for this article.
February 2018: Tierärztliche Praxis. Ausgabe G, Grosstiere/Nutztiere
https://www.readbyqxmd.com/read/29571186/infekti%C3%A3-ses-welpensterben-%C3%A2-vorbeugung-mit-eurican%C3%A2-herpes-205
#14
(no author information available yet)
No abstract text is available yet for this article.
February 2018: Tierärztliche Praxis. Ausgabe K, Kleintiere/Heimtiere
https://www.readbyqxmd.com/read/29542012/similar-efficacy-and-safety-of-basaglar-%C3%A2-and-lantus-%C3%A2-in-patients-with-type-2-diabetes-in-age-groups-65-years-%C3%A2-65-years-a-post-hoc-analysis-from-the-element-2-study
#15
Robyn K Pollom, Timothy Costigan, Lyndon B Lacaya, Liza L Ilag, Priscilla A Hollander
INTRODUCTION: To compare efficacy and safety of Basaglar® [insulin glargine 100 units/mL; LY insulin glargine (LY IGlar)] to Lantus® [insulin glargine 100 units/mL; SA insulin glargine (SA IGlar)] in older (≥ 65 years) or younger (< 65 years) patients with type 2 diabetes (T2D). METHODS: This subgroup analysis of a phase 3, randomized, double-blind, multinational, 24-week study compared LY IGlar and SA IGlar on several clinical efficacy (change in glycated hemoglobin (A1c), basal insulin dose, weight) and safety outcomes (incidence of adverse events, insulin antibodies, hypoglycemia incidence and rates) in patients either ≥ 65 or < 65 years...
April 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29488164/empagliflozin-induces-transient-diuresis-without-changing-long-term-overall-fluid-balance-in-japanese-patients-with-type-2-diabetes
#16
Atsutaka Yasui, Ganghyuck Lee, Tetsuaki Hirase, Tatsuroh Kaneko, Stefan Kaspers, Maximilian von Eynatten, Tomoo Okamura
INTRODUCTION: Empagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, ameliorates hyperglycemia in patients with type 2 diabetes (T2D) by inducing sustained glucosuria. Empagliflozin treatment was previously associated with a transient increase in 24-h urine volume in Caucasian patients with T2D, however comparable evidence in Japanese T2D individuals is scarce. We therefore assessed acute and chronic changes in 24-h urine volume and fluid intake with empagliflozin in Japanese patients with T2D...
April 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29485954/differences-in-all-cause-health-care-utilization-and-costs-in-a-type-2-diabetes-mellitus-population-with-and-without-a-history-of-cardiovascular-disease
#17
Sandhya Mehta, Sabyasachi Ghosh, Stephen Sander, Effie Kuti, William K Mountford
BACKGROUND: Multiple studies have reported that type 2 diabetes mellitus (T2DM) is a major risk factor for cardiovascular diseases (CVD), and presence of T2DM and CVD increases risk of death. There is growing interest in examining the effects of antidiabetic treatments on the reduction of cardiovascular events in T2DM adults with a history of CVD and thus at higher risk of cardiovascular events. OBJECTIVE: To estimate the incremental all-cause health care utilization and costs among adults with T2DM and a history of CVD compared with adults without a history of CVD, using a national linked electronic medical records (EMR) and claims database...
March 2018: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29460679/amcp-partnership-forum-improving-quality-value-and-outcomes-with-patient-reported-outcomes
#18
(no author information available yet)
Patient-reported outcomes (PROs), which provide a direct measure of a patient's health status or treatment preferences, represent a key component of the shift toward patient-centered health care. PROs can measure the state of a patient's disease-specific and overall health throughout the care continuum, enabling them to have a variety of uses for key health care stakeholders. Currently, PROs are used in drug development, aligning patient and clinician goals in care, quality-of-care measures, and coverage and reimbursement decisions...
March 2018: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29361462/safety-and-efficacy-of-tiotropium-in-children-aged-1-5-years-with-persistent-asthmatic-symptoms-a-randomised-double-blind-placebo-controlled-trial
#19
Elianne J L E Vrijlandt, Georges El Azzi, Mark Vandewalker, Ned Rupp, Thomas Harper, LeRoy Graham, Stanley J Szefler, Petra Moroni-Zentgraf, Ashish Sharma, Sebastian D Vulcu, Ralf Sigmund, Bo Chawes, Michael Engel, Hans Bisgaard
BACKGROUND: Few studies have assessed the safety and efficacy of potential asthma medications in children younger than 5 years. We descriptively assessed the safety and efficacy of tiotropium, a long-acting anticholinergic drug, in children aged 1-5 years with persistent asthmatic symptoms. METHODS: This exploratory 12-week, randomised, double-blind, placebo-controlled, parallel-group, phase 2/3, regulatory multicentre trial was done at 32 hospitals, clinics, and clinical research units in 11 countries in Asia, Europe, and North America...
February 2018: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/29304263/the-prevalence-of-adverse-ocular-hemorrhagic-events-in-patients-utilizing-oral-anticoagulant-and-antiplatelet-therapy-in-routine-clinical-practice
#20
Dattanand M Sudarshana, Eleni K Konstantinou, Sruthi Arepalli, Fabiana Q Silva, Andrew P Schachat, Justis P Ehlers, Rishi P Singh
BACKGROUND AND OBJECTIVE: Previous literature assessing ocular hemorrhagic complications of anticoagulant/antiplatelet medications in routine clinical practice is limited. This study evaluates the prevalence of spontaneous ocular hemorrhagic events associated with anticoagulation/antiplatelet therapy. PATIENTS AND METHODS: A retrospective study was performed to identify patients taking anticoagulants (rivaroxaban [Xarelto; Janssen Pharmaceuticals, Beerse, Belgium], bivalirudin [Angiomax; The Medicines Company, Parsippany, NJ], lepirudin [Refludan; Bayer HealthCare Pharmaceuticals, Berlin, Germany], dabigatran [Pradaxa; Boehringer Ingelheim, Ingelheim am Rhein, Germany], and argatroban) and antiplatelet agents (clopidogrel [Plavix; Bristol-Myers Squibb, New York City, NY], prasugrel [Effient; Lilly Medical, Indianapolis, IN], and ticagrelor [Brilinta; AstraZeneca, Cambridge, UK]) who presented for an eye examination...
January 1, 2018: Ophthalmic Surgery, Lasers & Imaging Retina
keyword
keyword
52341
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"